Insmed
Highly Engaged Employees
Manufacturing · New Jersey, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
700 Us Highway 202/206, Bridgewater, New...Phone Number
(908) 977-9900Website
www.insmed.comRevenue
$819.6 MillionStock Symbol
INSMIndustry
About Insmed
Insmed Org Chart
Senior Vice President, Gene Therapy
Senior Vice President Commercial Head of Gene...
Vice President, Field Medical (US)
Vice President, Head of Toxicology and Molecu...
Is Insmed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Insmed
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Insmed, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Insmed recently announced quarterly report
Product Launch: Get notified when Insmed launches new products
Check out if Insmed is spiking on competitors!
Click to see if Insmed had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Insmed has new funding data
Website visits: Recent activity has been detected on your website
Check if Insmed has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Insmed as Masked Content
Find 3 more new buyers
Compare Similar Companies to Insmed
Compare insights from companies similar to Insmed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Insmed is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Insmed is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Insmed.
Insmed financials insights
Gather financial insights about Insmed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Debt
$775M
Insmed Tech Stack
A closer look at the technologies used by Insmed
Most Recent Scoops
Insmed News & Media
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will...Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Insmed Incorporated (INSM) RBC Capital Markets Global Healthcare Conference 2026 May 20, 2026 10:30 AM EDTCompany ParticipantsSara Bonstein - Chief...Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus
Insmed (NASDAQ:INSM) Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company’s latest update. Speaking at a Bank of America healthcare conference, Lewis said the company intendedInsmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Insmed Incorporated (INSM) Bank of America Global Healthcare Conference 2026 May 12, 2026 4:40 PM EDTCompany ParticipantsWilliam Lewis - President, CEO...
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Insmed
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients... Read More
